MPM BioImpact Takes Reunion Neuroscience Private

Revive Therapeutics Agrees to Acquire Psilocin Pharma Corp.

February 11, 2020

Pharmaceuticals

Revive Therapeutics Ltd. entered into a letter of intent to acquire all issued and outstanding securities of Psilocin Pharma Corp. for an aggregate purchase price of $2.75 million to be satisfied by issuing 55 million common shares of Revive (deemed $0.05/share). Revive deposited 10 million shares ($500,000) into escrow as a deposit; the closing is subject to due diligence and execution of a definitive share exchange agreement.

HMP Global Acquires Neuroscience Education Institute (NEI)

July 11, 2023

Healthcare Services

HMP Global has entered into a definitive agreement to acquire the Neuroscience Education Institute (NEI), a privately held leader in psychopharmacology-based continuing medical education. NEI will become a fully owned subsidiary and operate as an independent entity within the HMP Global family while its management team remains in place; the deal expands HMP Global's psychiatry and behavioral health education offerings.

Red Nucleus Acquires PPM Advisory Group and OrtleyBio

April 15, 2021

Healthcare Services

Red Nucleus, the Riverside-backed provider of learning, performance and process solutions for the life sciences industry, acquired PPM Advisory Group and OrtleyBio (collectively “PPM”), a provider of scientific operations, medical affairs and commercialization communications focused on oncology and hematology. The deal is an add-on to Riverside's Red Nucleus platform and closed in April 2021; Fairmount Partners advised PPM in the sale.

3i Group Acquires Majority Stake in MPM

November 9, 2020

Food & Beverage

3i Group plc has agreed to invest c. £125m alongside MPM's management to acquire a majority stake in MPM, the Manchester-headquartered maker of premium pet food brands Applaws, Encore and Reveal. The transaction represents a sale by ECI Partners (which achieved a 4.4x return) and is intended to accelerate MPM's international expansion, particularly into North America; completion is subject to regulatory clearance.

Merck Acquires Prometheus Biosciences for $10.8 Billion

June 16, 2023

Biotechnology

Merck has agreed to acquire clinical-stage biotechnology company Prometheus Biosciences for $200.00 per share in cash, representing an approximate total equity value of $10.8 billion. The acquisition strengthens Merck's immunology pipeline by adding Prometheus' precision-medicine platform and lead candidate PRA023 (MK-7240) for inflammatory bowel disease and other immune-mediated conditions.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.